— Know what they know.
Not Investment Advice

RGNX NASDAQ

REGENXBIO Inc.
1W: +8.2% 1M: -27.7% 3M: -17.1% YTD: -50.3% 1Y: -32.5% 3Y: -65.8% 5Y: -81.3%
$6.35
-0.40 (-5.93%)
 
Weekly Expected Move ±21.1%
$3 $5 $6 $7 $8
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 25 · $328.3M mcap · 43M float · 2.57% daily turnover · Short 60% of daily vol

Cash Flow Trends

Operating Cash Flow
-$124M +28.4% ▲
Capital Expenditures
$2M +0.9% ▲
5Y CAGR: -38.2%
Free Cash Flow
-$126M +28.0% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 -100.0% ▼
Net Change in Cash
-$23M -200.2% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income$128M-$280M-$263M-$227M-$194M
Depreciation & Amort.$10M$13M$17M$16M$16M
Stock-Based Comp.$39M$41M$40M$38M$35M
Change in Working Capital$40M$14M-$11M$6M$12M
Other Non-Cash Items$4M$5M-$2M-$6M$8M
Operating Cash Flow$219M-$207M-$218M-$173M-$124M
— Investing Activities —
Capital Expenditures-$84M-$31M-$10M-$2M-$2M
Acquisitions (Net)-$5M$0$0$0$0
Investment Purchases-$498M-$185M-$87M-$190M-$333M
Investment Sales$176M$204M$287M$290M$319M
Other Investing$5M$0$0$6M$62K
Investing Cash Flow-$407M-$12M$191M$103M-$16M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$1M$0
Dividends Paid$0$0$0$0$0
Other Financing-$23M-$31M-$42M-$40M$116M
Financing Cash Flow$195M-$29M-$35M$93M$117M
Net Change in Cash$7M-$248M-$62M$23M-$23M
Cash End of Period$347M$99M$37M$60M$36M
Free Cash Flow$135M-$238M-$228M-$176M-$126M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms